Drug Profile
Research programme: RNA interference-based cancer therapeutics - Marina Biotech
Alternative Names: Debio 1141; M 400; MDR-09513; MDR-09521; MRNA-046Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MDRNA
- Developer Adhera Therapeutics; AstraZeneca China; Debiopharm Group; Marina Biotech
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bladder cancer; Liver cancer; Malignant ascites; Urogenital cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bladder-cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in liver cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-ascites in USA (Intraperitoneal)